BridgeBio Pharma (BBIO) return on equity (ROE)
BridgeBio Pharma (BBIO) earned a return on equity of -872.9% in fiscal 2020 (the year ended December 31, 2020). That is 802.3 percentage points lower than the -70.7% of fiscal 2019. Figures as of 18 Nov 2026, 02:56 UTC, from the company's filings with the SEC and Yahoo Finance.
Key facts
- Return on equity, fiscal 2020
- -872.9%
- Change on fiscal 2019
- −802.3 pts
- Highest on record
- -51.1%fiscal 2017
- Lowest on record
- -872.9%fiscal 2020
- Fiscal years on record
- 42017–2020
Figures as of . Older fiscal years come from the company's filings with the SEC, recent ones from Yahoo Finance. Figures, not advice.
BridgeBio Pharma return on equity (ROE), in more detail
Across the 4 fiscal years on record (2017–2020), the highest was -51.1% in fiscal 2017 and the lowest -872.9% in fiscal 2020. The fiscal 2020 figure is no higher than in any of the 3 earlier fiscal years on record, whose median is -53.8%.
Return on equity by fiscal year
BridgeBio Pharma return on equity (ROE), year by year
| Fiscal year | Return on equity | Change | Year ended |
|---|---|---|---|
| 2020 | -872.9% | 802.3 pts down | |
| 2019 | -70.7% | 16.8 pts down | |
| 2018 | -53.8% | 2.8 pts down | |
| 2017 | -51.1% | — |
Change is on the fiscal year before, in percentage points; a dash means that year is not on record. A dash anywhere else means the figure was not reported or cannot be computed — it is never filled in.
How it is calculated
Return on equity is net income divided by shareholders' equity at the fiscal year-end; it is left blank when equity is negative.
How to read it
It is the profit earned on the owners' capital — above about 15% is strong, though heavy debt or large buybacks can inflate it.
Return on equity at health care companies of similar size
| Company | Return on equity | Fiscal year |
|---|---|---|
| ICON ICLR | 2.5% | 2025 |
| Jazz Pharmaceuticals JAZZ | -8.2% | 2025 |
| Solventum SOLV | 30.8% | 2025 |
| BridgeBio Pharma BBIO | -872.9% | 2020 |
| Summit Therapeutics SMMT | -163.9% | 2025 |
| Glaukos GKOS | -28.6% | 2025 |
The latest fiscal year on record for each company, in the currency it reports in. Fiscal years end at different times of year.
BridgeBio Pharma, figure by figure
- BridgeBio Pharma market cap
- BridgeBio Pharma revenue
- BridgeBio Pharma earnings
- BridgeBio Pharma earnings per share (EPS)
- BridgeBio Pharma P/E ratio
- BridgeBio Pharma P/S ratio
- BridgeBio Pharma P/B ratio
- BridgeBio Pharma free cash flow
- BridgeBio Pharma operating margin
- BridgeBio Pharma dividend
- BridgeBio Pharma shares outstanding
- BridgeBio Pharma total debt
- BridgeBio Pharma cash on hand
- BridgeBio Pharma total assets
- BridgeBio Pharma return on invested capital (ROIC)
BridgeBio Pharma (BBIO) overview: price, valuation and scorecardAll health care companies by market value
BridgeBio Pharma return on equity (ROE): questions and answers
What is BridgeBio Pharma's return on equity?
BridgeBio Pharma (BBIO) earned a return on equity of -872.9% in fiscal 2020 (the year ended December 31, 2020). That is 802.3 percentage points lower than the -70.7% of fiscal 2019.
Is BridgeBio Pharma's return on equity high or low compared with its own history?
The fiscal 2020 figure is no higher than in any of the 3 earlier fiscal years on record, whose median is -53.8%.
What are the highest and lowest return on equity figures on record for BridgeBio Pharma?
Across the 4 fiscal years on record (2017–2020), the highest was -51.1% in fiscal 2017 and the lowest -872.9% in fiscal 2020.
How is BridgeBio Pharma's return on equity calculated?
Return on equity is net income divided by shareholders' equity at the fiscal year-end; it is left blank when equity is negative.
Fiscal years are named for the calendar year they end in.
Learn: return on equity (ROE)
All stocks guides →- Return on invested capital (ROIC) vs ROE and ROA
Return on invested capital (ROIC) is after-tax operating profit divided by the money tied up in the business: debt plus equity, less cash. A company earning $15 million after tax on $100 million of invested capital has a 15% ROIC. Unlike return on equity, it does not rise just because a company borrows more.
- Altman Z-score: formula, zones and where it fails
The Altman Z-score is a weighted sum of five financial ratios that Edward Altman fitted in 1968 to separate companies that went bankrupt from those that did not. Funkfolio reads above 2.99 as the safe zone, below 1.81 as the distress zone, and between them a grey zone. It does not suit banks or insurers.
- Analyst price targets and ratings: what they mean
An analyst price target is a research analyst's estimate of where a share price will be at a set horizon, such as twelve months; a rating such as buy or hold is that analyst's recommendation. A consensus is an average or median of the targets a data provider has collected. Studies have found targets on average well above later prices.
Cite this page
Funkfolio, “BridgeBio Pharma (BBIO) return on equity (ROE)”, data as of 18 November 2026. https://funkfolio.com/stock/BBIO/roe
Underlying data: the company's filings with the SEC and Yahoo Finance.